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ABSTRACT
Background: Robot-assisted radical prostatectomy (RARP) is a feasible treatment option 
for high-risk prostate cancer (PCa). While patients may achieve undetectable prostate-
specific antigen (PSA) levels after RARP, the risk of disease progression is relatively high. We 
investigated metastasis-free survival, cancer-specific survival (CSS), and overall survival (OS) 
outcomes and prognosticators in such patients.
Methods: In a single-center cohort of 342 patients with high-risk PCa (clinical stage ≥ T3, 
biopsy Gleason score ≥ 8, and/or PSA levels ≥ 20 ng/mL) treated with RARP and pelvic 
lymph node dissection between August 2005 and June 2011, we identified 251 (73.4%) 
patients (median age, 66.5 years; interquartile range [IQR], 63.0–71.0 years) who achieved 
undetectable PSA levels (< 0.01 ng/mL) postoperatively. Survival outcomes were evaluated 
for the entire study sample and in groups stratified according to the time to biochemical 
recurrence dichotomized at 60 months.
Results: During the median follow-up of 75.9 months (IQR, 59.4–85.8 months), metastasis 
occurred in 38 (15.1%) patients, most often to the bones, followed by the lymph nodes, lungs, 
and liver. The 5-year metastasis-free, cancer-specific, and OS rates were 87.1%, 94.8%, and 
94.3%, respectively. Multivariate Cox-regression analysis revealed time to recurrence as an 
independent predictor of metastasis (P < 0.001). Time to metastasis was an independent 
predictor of OS (P = 0.003). Metastasis-free and CSS rates were significantly lower among 
patients with recurrence within 60 months of RARP (log-rank P < 0.001).
Conclusion: RARP confers acceptable oncological outcomes for high-risk PCa. Close 
monitoring beyond 5 years is warranted for early detection of disease progression and for 
timely adjuvant therapy.
Keywords: Prostate Cancer; Prostatectomy; Recurrence; Survival




Do Kyung Kim , Kyo Chul Koo , Kwang Suk Lee , Yoon Soo Hah ,  
Koon Ho Rha , Sung Joon Hong , and Byung Ha Chung 
Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
Time to Disease Recurrence Is a 
Predictor of Metastasis and Mortality 
in Patients with High-risk Prostate 
Cancer Who Achieved Undetectable 
Prostate-specific Antigen Following 
Robot-assisted Radical Prostatectomy
Received: Jan 23, 2018
Accepted: Aug 7, 2018
Address for Correspondence: 
Byung Ha Chung, MD, PhD
Department of Urology, Gangnam Severance 
Hospital, Yonsei University College of 
Medicine, 211 Eonju-ro, Gangnam-gu,  
Seoul 06273, Korea.
E-mail: chung646@yuhs.ac
© 2018 The Korean Academy of Medical 
Sciences.
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Do Kyung Kim 
https://orcid.org/0000-0002-3696-8756
Kyo Chul Koo 
https://orcid.org/0000-0001-7303-6256
Kwang Suk Lee 
https://orcid.org/0000-0002-7961-8393
Yoon Soo Hah 
https://orcid.org/0000-0001-6424-4619
Koon Ho Rha 
https://orcid.org/0000-0001-8588-7584
Sung Joon Hong 
https://orcid.org/0000-0002-7622-4153




This study was supported by the Young 
Researcher Program Grant of the National 
Research Foundation of Korea (NRF-
2017R1C1B5017516).
Disclosure
The authors have no potential conflicts of 
interest to disclose.
Author Contributions
Conceptualization: Kim DK, Koo KC, Chung BH. 
Data curation: Kim DK, Koo KC. Methodology: 
Kim DK, Koo KC, Lee KS, Hah YS. Investigation: 
Kim DK, Koo KC, Lee KS, Hah YS, Rha KH, Hong 
SJ, Chung BH. Writing - original draft: Kim DK.
INTRODUCTION
With the advent of the prostate-specific antigen (PSA) screening era, an increasing 
number of newly diagnosed prostate cancer (PCa) cases tend to be assessed as lower-risk 
disease.1 Nevertheless, between 20% and 35% of PCa patients in the United States present 
with clinically high-risk disease.1-3 In these high-risk patients, survival outcomes are 
heterogeneous, and there is no consensus on the optimal management strategy.4
In the last decade, radiotherapy (RT) administered in combination with androgen 
deprivation therapy (ADT) has been the strategy of choice for the management of localized 
high-risk PCa. However, with the advancement of minimally invasive surgical techniques, 
surgery has gained acknowledgement as a feasible alternative.5 In a recent study using 
propensity-score matched analysis to compare oncological outcomes of patients with 
localized or locally advanced PCa treated with radical prostatectomy (RP) and RT, the two 
treatments demonstrated comparable cancer-specific survival (CSS) for all risk groups 
defined by the National Comprehensive Cancer Network (NCCN).6 Moreover, robot-assisted 
radical prostatectomy (RARP) was demonstrated to be a curative treatment option for a 
subset of high-risk patients with long-term undetectable PSA levels. Another advantage of 
surgical treatment is the opportunity to perform precise pathological evaluation and use 
postoperative nomograms, which facilitate the initiation of appropriate and timely adjuvant 
therapy.7 Indeed, 14% to 37% of high-risk PCa patients treated with RP demonstrate 
favorable pathologic results and better oncological outcomes than those noted among other 
high-risk patients.8-10
Patients with high-risk PCa treated with RP may achieve undetectable PSA levels 
postoperatively. Compared to patients with a low or intermediate risk, a higher proportion of 
patients with a high-risk will experience biochemical recurrence (BCR), although the clinical 
course of patients with BCR is highly variable.11 Specifically, some patients experience 
rapid clinical progression to metastases, whereas BCR may pose no threat throughout the 
remaining life span of other patients.12 Studies have reported time to BCR as a significant 
prognosticator of cancer-specific mortality (CSM). However, few data are available regarding 
the relevance of time to BCR in patients with high-risk PCa undergoing RP.13,14
The purpose of the present study was to confirm the feasibility of RARP for high-risk PCa 
and to investigate the effect of time to disease progression on metastasis and mortality rates 
in patients with high-risk PCa who achieved undetectable PSA following RARP. To address 
these issues, we investigated metastasis-free survival (MFS), CSS, and overall survival (OS) 
outcomes, as well as the prognosticators of these survival endpoints.
METHODS
Patient selection
We retrospectively reviewed the records of 342 patients treated with RARP and pelvic 
lymph node dissection between August 2005 and June 2011 at a single tertiary institution. 
We identified 251 (73.4%) patients with high-risk PCa who achieved undetectable PSA 
postoperatively, defined as < 0.01 ng/mL by ultrasensitive assay. High-risk PCa was defined 
as clinical stage ≥ T3, biopsy Gleason score ≥ 8, and/or PSA levels ≥ 20 ng/mL, according 
to the NCCN guidelines.15 PCa staging was determined according to the 7th American 
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Joint Committee on Cancer TNM system, with the definition of distant metastasis based 
on either demonstrable metastatic deposits on imaging (bone scan, computerized 
tomography, magnetic resonance imaging, or positron emission tomography) or pathologic 
confirmation of PCa in tissue samples collected from outside the prostatic fossa. The 
following exclusion criteria were applied: 1) incomplete clinical data; 2) loss to follow-up;  
3) unknown cause of death.
Prognostic factors and outcome variables
All patients had complete clinical and pathological data including age, body mass index 
(BMI), preoperative PSA levels, clinical stage, biopsy Gleason score, pathological stage with 
Gleason score, positive surgical margin status, tumor volume, seminal vesicle invasion 
status, lymph node invasion status, prostatic intraepithelial neoplasia grading, and time 
to BCR. These patients were further stratified into two groups according to time to BCR 
dichotomized at 60 months. BCR was defined as the first of two or more consecutive 
increases in PSA levels of > 0.2 ng/mL noted later than 3 months following surgery. Time 
to metastasis was defined as the time period from the date of histological diagnosis to the 
time of metastasis detection. OS was determined as the time elapsed between the date of 
histological diagnosis and the date of death. For all patients, the survival status and the cause 
of death were obtained from the National Cancer Registry Database or from the electronic 
medical records of the treating institution.
Study endpoints
The primary endpoints were the rates of MFS, CSS, and OS, whereas the secondary endpoints 
included the prognosticators of these survival endpoints.
Statistical analysis
Demographic characteristics of patients and tumors were compared using descriptive 
statistics including median and interquartile range (IQR). Appropriate comparative tests 
such as the Student's t-test and the χ2 test, were used to compare continuous and categorical 
variables, respectively. Kaplan-Meier curves were used to estimate MFS and OS. Univariate 
and multivariate analyses were performed using Cox-proportional hazards regression 
models in order to adjust for potential confounders in predicting survival. Variables 
considered potential predictors for the purpose of multivariate modeling were selected by 
univariate analysis. Results regarding prognosticators were expressed in terms of hazard 
ratio (HR) with 95% confidence intervals (CIs). Statistical analysis was performed using 
SPSS version 18 (SPSS Inc., Chicago, IL, USA). All tests were two-sided, with statistical 
significance set at P < 0.05.
Ethics statement
This retrospective study was approved by the Institutional Ethics Committee after review of 
the protocol and procedures employed (approval No. 2014-0112).
RESULTS
Patient demographics
Table 1 summarizes the demographic and clinical characteristics of 251 patients with high-risk 
PCa who achieved undetectable PSA levels postoperatively. The median age and PSA levels were 
66.5 years (IQR, 63.0–71.0 years) and 8.7 ng/mL (IQR, 6.1–18.3 ng/mL), respectively.
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Postoperative characteristics
The patients were followed-up for a median of 75.9 months (IQR, 59.4–85.8 months) and 
stratified into two groups according to the time to BCR (dichotomized at 60 months). The 
incidence of pathological N1 disease was higher in patients who experienced BCR at ≤ 60 
months than in those who did not (P = 0.044), but no differences between the two groups 
were noted regarding other postoperative tumor characteristics (Table 2).
Oncological outcomes
The oncological outcomes of our cohort are summarized in Table 3. BCR was observed in 65 
(25.9%) patients, with an overall 5-year BCR-free survival rate of 73.9%. Metastasis occurred in 
38 (15.1%) patients, mostly to the bones (65.8%), followed by the lymph nodes (36.8%), lungs 
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Table 1. Preoperative characteristics of patients with high-risk PCa who achieved undetectable PSA following 
robot-assisted radical prostatectomy
Characteristics Overall
Age, yr 66.5 (63.0–71.0)
PSA, ng/mL 8.7 (6.1–18.3)
BMI, kg/m2 24.1 (22.3–25.9)





Biopsy Gleason score, No. (%)
≤ 6 85 (33.9)
7 120 (47.8)
3 + 4 82 (32.7)
4 + 3 38 (15.1)
≥ 8 46 (18.3)
Clinical nodal status, No. (%)
N0 225 (89.6)
N1 26 (10.4)
PCa = prostate cancer, PSA = prostate-specific antigen, BMI = body mass index.
Table 2. Postoperative pathological outcomes of patients with high-risk PCa who achieved undetectable PSA following robot-assisted radical prostatectomy
Characteristics Overall Time to BCR P value
< 60 mon ≥ 60 mon
No. of patients 251 148 (59.0) 103 (41.0) NS
Pathologic tumor stage, No. (%) 0.469
pT2 48 (19.1) 30 (20.2) 18 (17.4)
pT3 183 (72.9) 109 (73.6) 74 (71.8)
pT4 20 (8.0) 9 (6.2) 11 (10.8)
Pathologic Gleason score, No. (%) 0.639
≤ 6 44 (17.5) 22 (14.9) 22 (21.4)
7 127 (50.6) 80 (54.1) 47 (45.6)
≥ 8 80 (31.9) 46 (31.0) 34 (33.0)
7 (3 + 4) 86 (34.3) 54 (36.5) 32 (31.1) 0.875
7 (4 + 3) 41 (16.3) 26 (17.6) 15 (14.6)
Pathologic nodal status, No. (%) 0.044
N0 233 (92.8) 134 (90.5) 99 (96.1)
N1 18 (7.2) 14 (9.5) 4 (3.9)
Positive surgical margin, No. (%) 80 (31.9) 50 (33.7) 30 (29.1) 0.132
Tumor volume 1.5 (0.87–2.78) 1.7 (0.95–3.1) 1.2 (0.7–2.4) 0.367
Seminal vesicle invasion, No. (%) 30 (12.0) 20 (13.5) 10 (9.7) 0.090
Lymphovascular invasion, No. (%) 17 (6.9) 8 (5.4) 9 (8.7) 0.149
High grade PIN, No. (%) 159 (63.3) 90 (60.8) 69 (67.0) 0.059
Total follow-up, mon 75.9 (59.4–85.8) 76.4 (63.6–82.5) 74.1 (53.1–81.1) 0.891
PCa = prostate cancer, PSA = prostate-specific antigen, BCR = biochemical recurrence, PIN = prostatic intraepithelial neoplasia.
(15.8%), and liver (13.2%). Overall, 101 (40.2%) patients received adjuvant treatment with 
either ADT or RT plus ADT. The 5-year MFS, CSS, and OS rates were 87.1%, 94.8%, and 94.3%, 
respectively. Patients who exhibited BCR at ≤ 60 months after RARP exhibited significantly 
lower MFS and OS rates compared to those of patients who did not (log-rank P < 0.001; Figs. 1 
and 2). The most common cause of death was second primary malignancy, followed by PCa and 
cardiopulmonary disease. Among the 342 high-risk patients reviewed in our study, 186 (54.4%) 
patients achieved cure, defined as persistent undetectable PSA levels at the median follow-up.
Perioperative prognosticators of MFS and CSS
Univariate Cox-regression analyses revealed pathologic Gleason score (≥ 8 vs. < 7) (HR, 2.227; 
95% CI, 1.197–4.412; P = 0.011), pathologic node stage (HR, 2.883; 95% CI, 1.523–5.459;  
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Table 3. Oncological outcomes of patients with high-risk PCa who achieved undetectable PSA following robot-
assisted radical prostatectomy
Characteristics Overall
BCR, No. (%) 65 (25.9)
BCR-free survival (%), 5-year 73.9
Metastasis, No. (%) 38 (15.1)





MFS (%), 5-year 87.1
Adjuvant therapy, No. (%)
None 150 (59.8)
ADT only 31 (12.3)
RT + ADT 70 (27.9)
Causes of death, No. (%)
Second primary malignancy 14 (5.6)
PCa 7 (2.8)
Cardiopulmonary disease 4 (1.6)
Cancer-specific survival (%), 5-year 94.8
OS (%), 5-year 94.3
PCa = prostate cancer, PSA = prostate-specific antigen, BCR = biochemical recurrence, LN = lymph node,  
MFS = metastasis-free survival, ADT = androgen deprivation therapy, RT = radiotherapy, OS = overall survival.
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Time to metastasis, mon
Time to BCR ≥ 60 mon
Time to BCR < 60 mon
Fig. 1. Kaplan-Meier curves for MFS rate according to time to BCR (log-rank P < 0.001). 
MFS = metastasis-free survival, BCR = biochemical recurrence.
P = 0.001), seminal vesicle invasion (HR, 5.656; 95% CI, 2.003–15.97; P = 0.001), shorter time 
to BCR (HR, 0.956; 95% CI, 0.939–0.973; P < 0.001) as an independent predictor of a higher 
risk of metastasis (Table 4), while a shorter time to BCR (HR, 0.956; 95% CI, 0.925–0.989;  
P = 0.009) and metastasis (HR, 0.857; 95% CI, 0.813–0.903; P < 0.001) was revealed to be an 
independent predictor of a higher risk of CSM (Table 5).
Multivariate Cox-regression analyses revealed longer time to BCR as an independent 
predictor of a lower risk of metastasis (HR, 0.918; 95% CI, 0.878–0.961; P < 0.001) (Table 4), 
while a longer time to metastasis was revealed to be an independent predictor of a lower risk 
of CSM (HR, 0.885; 95% CI, 0.816–0.959; P = 0.003) (Table 5).
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Time to death, mon
Time to BCR ≥ 60 mon
Time to BCR < 60 mon
Fig. 2. Kaplan-Meier curves for OS rate according to time to BCR (log-rank P < 0.001). 
OS = overall survival, BCR = biochemical recurrence.
Table 4. Association of perioperative factors with the risk of metastasis among patients with high-risk PCa who achieved undetectable PSA levels following 
radical prostatectomy
Variables Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age, yr 1.012 0.963–1.062 0.646 - - -
BMI 1.041 0.917–1.181 0.537 - - -
PSA 1.003 0.998–1.009 0.255 - - -
Pathologic T stage (≥ pT3 vs. ≤ pT2) 2.014 0.707–5.739 0.191 - - -
Pathologic Gleason score (≥ 8 vs. < 7) 2.227 1.197–4.142 0.011 2.046 0.556–7.532 0.282
Pathologic Gleason score (7 [4 + 3] vs. 7 [3 + 4]) 0.428 0.127–2.019 0.346 - - -
Pathologic N stage (N1) 2.883 1.523–5.459 0.001 0.519 0.120–2.244 0.387
Tumor volume 1.053 0.952–1.166 0.316 - - -
Positive surgical margin 1.147 0.588–2.237 0.686 - - -
Seminal vesicle invasion 5.656 2.003–15.97 0.001 1.626 0.475–5.565 0.439
Lymphovascular invasion 1.914 0.441–8.301 0.386 - - -
No. of positive LNs 1.169 0.583–2.234 0.662 - - -
High grade PIN 1.055 0.415–2.684 0.911 - - -
PSA nadir period 0.992 0.956–1.029 0.661 - - -
Time to BCR 0.956 0.939–0.973 < 0.001 0.918 0.878–0.961 < 0.001
Salvage radiation therapy 0.263 0.067–1.032 0.053 0.212 0.032–1.393 0.105
PCa = prostate cancer, PSA = prostate-specific antigen, CI = confidence interval, HR = hazard ratio, BMI = body mass index, LN = lymph node, PIN = prostatic 
intraepithelial neoplasia, BCR = biochemical recurrence.
DISCUSSION
RP is one of the most commonly used treatments for patients with localized PCa and has 
been proven to provide favorable prognosis in a subset of high-risk patients.16-18 In the 
present study, we confirmed that RP may confer undetectable PSA levels postoperatively, 
and, consequently, a chance for cure in a substantial proportion of patients. Pompe et al.19 
examined oncologic outcome of high-risk or very high-risk patients who underwent RP. 
The authors reported that despite the relatively poor prognosis of patients with high-risk 
PCa, RP results in favorable 5 and 8 years MFS, CSM-free survival and OS rates. At the same 
time, our data suggest that RP alone may not be sufficient for local control of PCa, and that 
maximal oncological control is rather achieved by timely administration of multidisciplinary 
adjuvant treatment, even beyond 5 years postoperatively. Amling et al.20 suggested patients 
undergoing RP should be subjected to long-term follow-up to allow the option of early 
intervention should progression occur due to a significant number of patients, including 
those with organ confined cancers which may exhibit disease progression even after 5 years.
We observed that 73.9% of patients achieved undetectable PSA levels postoperatively, 
which adds to the literature regarding the feasibility of RP for the treatment of high-risk 
disease. Specifically, RP provides several distinct advantages over ADT or RT. First, accurate 
pathological staging following RP enables timely administration of adjuvant therapy, at the 
same time avoiding morbidities associated with unnecessary adjuvant treatment.21 Recent 
studies have shown that up to 35% of patients are inaccurately staged, and up to 50% of 
patients originally identified to have high-risk disease demonstrate lower-risk disease 
on final pathological review.11,22 Second, RP may provide superior local cancer control 
compared to that allowed by other treatment modalities. Boorjian et al.16 evaluated the long-
term survival outcomes of high-risk PCa treated with RP or external beam RT with or without 
adjuvant ADT, and observed that patients treated with RT had a significantly increased risk of 
all-cause mortality compared to that noted among patients who received RP. Third, RP offers 
better health-related quality of life (HRQoL). Indeed, a long-term assessment of HRQoL 
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Table 5. Association of perioperative factors with the risk of CSM among patients with high-risk PCa who achieved undetectable PSA levels following radical 
prostatectomy
Variables Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age, yr 0.956 0.881–1.037 0.277 - - -
BMI 1.055 0.783–1.421 0.724 - - -
PSA 1.006 0.994–1.019 0.331 - - -
Pathologic T stage (≥ pT3 vs. ≤ pT2) 1.334 0.835–2.165 0.223 - - -
Pathologic Gleason score (≥ 8 vs. < 7) 1.497 0.136–16.51 0.742 - - -
Pathologic Gleason score (7 [4 + 3] vs. 7 [3 + 4]) 1.145 0.526–2.211 0.566 - - -
Pathologic N stage (N1) 6.581 0.596–72.61 0.124 - - -
Tumor volume 3.771 0.323–43.97 0.291 - - -
Positive surgical margin 2.129 0.341–13.26 0.419 - - -
Seminal vesicle invasion 2.776 0.288–26.73 0.377 - - -
Lymphovascular invasion 1.112 0.588–1.937 0.644 - - -
No. of positive LNs 2.175 0.562–8.415 0.261 - - -
High grade PIN 0.932 0.096–9.051 0.951 - - -
PSA nadir period 0.539 0.137–2.121 0.376 - - -
Time to BCR 0.956 0.925–0.989 0.009 0.948 0.892–1.007 0.083
Salvage radiation therapy 2.286 0.198–26.43 0.509 - - -
Time to metastasis 0.857 0.813–0.903 < 0.001 0.885 0.816–0.959 0.003
CSM = cancer-specific mortality, PCa = prostate cancer, PSA = prostate-specific antigen, HR = hazard ratio, CI = confidence interval, BMI = body mass index,  
LN = lymph node, PIN = prostatic intraepithelial neoplasia, BCR = biochemical recurrence.
in men receiving RT and brachytherapy showed that their prostate-specific HRQoL scores 
continued to decline, whereas those of RP patients remained relatively stable or gradually 
improved.23 Fourth, men undergoing RP are less likely to require ADT, and have significantly 
longer ADT-free survival compared to the values noted in patients undergoing external beam 
RT.5 Lastly, primary tumors have been suggested to play a significant role in tumor shedding 
and cytokine/growth factor production. In this respect, the advantage of RP is that it provides 
definitive tumor debulking, which may improve overall outcomes.24
In our study, patients were stratified according to the time to BCR, dichotomized at 60 months. 
The NCCN guideline recommends closed follow-up for up to 5 years, followed by annual 
follow-up for subsequent years.15 Our results indicate that BCR may occur even after 60 months 
in high-risk patients. Therefore, we investigated the subgroup of patients who would benefit 
from observation beyond 5 years. We found a marginal difference between the two groups 
regarding pathologic nodal status. However, there were no differences in pathologic features 
well known to affect oncological outcomes, namely tumor stage, tumor grade, and positive 
surgical margin status. In particular, there was no significant difference in pathologic Gleason 
score between 7 (4 + 3) and 7 (3 + 4). However, we did find differences in MFS and OS rates 
according to time to BCR. Specifically, patients who exhibited BCR within < 60 months after 
surgery had significantly lower MFS and OS rates. Briganti et al.13 evaluated the role of time 
to BCR in CSM and observed that patients who experienced BCR within 3 years from surgery 
had significantly higher CSM rates than those noted among patients who developed BCR at a 
later time. Freedland et al.14 also found that the time to BCR following surgery was significantly 
associated with CSM, and that stratifying patients according to BCR dichotomized at 3 years 
after surgery provided the best risk stratification approach. The difference between the cutoff 
period reported by Freedland et al.14 (3 years) and that observed in our study (60 months, i.e., 
5 years) may be presumed to arise from the difference in the study cohorts, and specifically 
because we only included patients who achieved undetectable PSA levels following RP. We 
also noted that the time to metastasis was a significant prognosticator of the risk of CSM, in 
accordance with the observations of Pound et al.25, who reported that, after the development of 
metastatic disease, the actuarial median time until death due to PCa was 5 years, and that time 
to metastasis was an important determinant of CSM.
Our findings have important clinical implications. In our study, 41% of patients experienced 
BCR later than 5 years following RARP. The NCCN guideline recommends that PSA levels 
should be monitored every 6 to 12 months until 5 years postoperatively, and annually 
thereafter.15 Our observation that a substantial proportion of patients are likely to experience 
BCR later than 5 years after surgery suggests that the monitoring interval beyond 5 years 
postoperatively should be shortened for high-risk PCa patients even if PSA levels remain 
undetectable beyond this period, in order to enable early detection of disease progression and 
timely administration of multidisciplinary adjuvant treatment. Finally, our findings indicate 
that the time from RP to BCR is a prognosticator for MFS and OS and may therefore be utilized 
as a proxy for decision making regarding the length of monitoring intervals (in months).
Our study has several limitations. First, its retrospective nature precludes exclusion of 
potential selection bias regarding the indication for surgical treatment, which was made 
at the discretion of the treating surgeon. Second, there was discrepancy regarding the 
monitoring intervals, adjuvant treatment protocol, and treatment duration. Third, patients 
included in our study received RARP performed by different surgeons, albeit at the same 
institution, which may have affected the time to BCR and postoperative outcomes such as 
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positive surgical margin or pathologic nodal status. Indeed, Klein et al.26 reported that the 
surgeon's experience, independent of surgical volume, affects BCR. However, we consider 
this aspect as an inherent bias of data collected in the clinical setting, which, in turn, may 
reflect everyday clinical practice in general. Finally, the median follow-up period was 75.9 
months, which is relatively short to draw definitive conclusions regarding MFS or CSS.
In conclusion, a substantial proportion of high-risk PCa patients may achieve undetectable 
PSA levels following RP. Nevertheless, the risk of BCR and metastasis is relatively high. We 
confirmed that time to BCR and metastasis were direct or indirect prognosticators of survival 
rates, and may therefore, be utilized as a proxy for decision making regarding monitoring 
intervals. Considering that a substantial proportion of patients with postoperatively 
undetectable PSA are likely to experience BCR later than 60 months after surgery, close 
monitoring even beyond this period is warranted to enable early detection of disease 
progression and timely administration of multidisciplinary adjuvant treatment.
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